Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06860971 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 1 wordv4 See this version in full on ClinicalTrials.gov ↗
  2. Eligibility criteria expanded, about 6 wordsv3 See this version in full on ClinicalTrials.gov ↗
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 35 · Start date changed from estimate of Mar 2025 to Apr 18, 2025v2 Show 2 more changesShow less
    • Study sites: 1 to 35
    • Start date changed from estimate of Mar 2025 to Apr 18, 2025
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.
Trial Details
NCT Number NCT06860971
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Thyroid Cancer
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov